Patent · US Active

Respiratory syncytial virus (RSV) vaccine

US11034729B2 · kind B2 · utility

25Cited by

2References

20Claims

0Family size

Assignee

CureVac AG · DE

Inventors

Thomas Kramps · Bellinzona, CH
Margit SCHNEE · Konstanz, DE
Daniel Voss · Tübingen, DE
Benjamin PETSCH · Tübingen, DE

Key dates

Filing date	Oct 23, 2018
Grant date	Jun 15, 2021
Priority date	—
Expiry date	Nov 24, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/18534
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.